Related Experiment Video
Updated: Jul 18, 2025

08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.3K
Stereotactic Body Radiation Therapy for Spine Metastases-Findings from an Australian Population-Based Study
Wee Loon Ong1,2,3, Roger L Milne4,5,6, Farshad Foroudi7
1Alfred Health Radiation Oncology, Melbourne 3004, Australia.
Current Oncology (Toronto, Ont.)
|August 25, 2023
Summary
Stereotactic body radiation therapy (SBRT) for spine metastases is increasing in Australia, but still used infrequently. Factors like cancer type, socioeconomic status, and treatment center influence SBRT use.
Area of Science:
- Radiation Oncology
- Medical Physics
- Oncology
Background:
- Spine metastases represent a significant clinical challenge, often requiring palliative radiotherapy.
- Stereotactic body radiation therapy (SBRT) offers a precise, high-dose radiation approach for localized tumors.
- Evaluating SBRT utilization for spine metastases is crucial for understanding current treatment trends.
Purpose of the Study:
- To assess the utilization patterns and trends of SBRT for spine metastases in Australia.
- To identify patient and treatment-related factors associated with SBRT use for spine metastases.
Main Methods:
- Utilized the Victorian Radiotherapy Minimum Dataset (VRMD) for a population-based analysis.
- Examined radiotherapy courses for spine metastases between 2012 and 2017.
- Performed multivariate analyses to identify factors associated with SBRT use.
Main Results:
- SBRT use for spine metastases increased from 0.4% in 2012 to 5% in 2017.
- Higher SBRT utilization was observed in patients with prostate cancer and melanoma.
- SBRT use was associated with higher socioeconomic status and private treatment centers.
Conclusions:
- This study provides the first Australian population-based data on the rising use of spine SBRT.
- Despite the increase, overall spine SBRT utilization remains low.
- Anticipated future growth in spine SBRT use as it becomes a standard of care for painful metastases.

